These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21047696)

  • 21. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program.
    Ueno S; Tanabe G; Sako K; Hiwaki T; Hokotate H; Fukukura Y; Baba Y; Imamura Y; Aikou T
    Hepatology; 2001 Sep; 34(3):529-34. PubMed ID: 11526539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: comparison of five staging systems.
    Zhang XF; Qi X; Meng B; Liu C; Yu L; Wang B; Lv Y
    Eur J Surg Oncol; 2010 Aug; 36(8):718-24. PubMed ID: 20538423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Usefulness of the CLIP scoring system for prediction of postoperative prognosis of patients with large hepatocellular carcinoma.
    Noda T; Sasaki Y; Yamada T; Eguchi H; Yano M; Ohigashi H; Ishikawa O; Imaoka S
    J Hepatobiliary Pancreat Surg; 2009; 16(4):538-45. PubMed ID: 19367360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival rates according to the Cancer of the Liver Italian Program scores of 345 hepatocellular carcinoma patients after multimodality treatments during a 10-year period in a retrospective study.
    Yamagiwa K; Shiraki K; Yamakado K; Mizuno S; Hori T; Yagi S; Hamada T; Iida T; Nakamura I; Fujii K; Usui M; Isaji S; Ito K; Tagawa S; Takeda K; Yokoi H; Noguchi T
    J Gastroenterol Hepatol; 2008 Mar; 23(3):482-90. PubMed ID: 18086115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma.
    Decaens T; Roudot-Thoraval F; Badran H; Wolf P; Durand F; Adam R; Boillot O; Vanlemmens C; Gugenheim J; Dharancy S; Bernard PH; Boudjema K; Calmus Y; Hardwigsen J; Ducerf C; Pageaux GP; Hilleret MN; Chazouillères O; Cherqui D; Mallat A; Duvoux C
    Liver Int; 2011 Jul; 31(6):792-801. PubMed ID: 21645209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A New Prognostic Model Based on Albumin-Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria.
    Ho SY; Liu PH; Hsu CY; Hsia CY; Huang YH; Su CW; Lei HJ; Lee RC; Hou MC; Huo TI
    Dig Dis Sci; 2020 Feb; 65(2):658-667. PubMed ID: 31659612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method--analysis of 2010 Taiwanese patients.
    Chen CH; Hu FC; Huang GT; Lee PH; Tsang YM; Cheng AL; Chen DS; Wang JD; Sheu JC
    Eur J Cancer; 2009 Jun; 45(9):1630-9. PubMed ID: 19157858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment and prognostic factors in patients with hepatocellular carcinoma.
    Martins A; Cortez-Pinto H; Marques-Vidal P; Mendes N; Silva S; Fatela N; Glória H; Marinho R; Távora I; Ramalho F; de Moura MC
    Liver Int; 2006 Aug; 26(6):680-7. PubMed ID: 16842324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery.
    Huang YH; Chen CH; Chang TT; Chen SC; Wang SY; Lee HS; Lin PW; Huang GT; Sheu JC; Tsai HM; Lee PC; Chau GY; Lui WY; Lee SD; Wu JC
    J Gastroenterol Hepatol; 2005 May; 20(5):765-71. PubMed ID: 15853992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prognosis of hepatocellular carcinoma according to new staging classifications].
    Caselitz M; Masche N; Flemming P; Stern C; Manns MP; Wagner S; Kubicka S
    Dtsch Med Wochenschr; 2004 Aug; 129(33):1725-30. PubMed ID: 15295682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization.
    Kim JH; Kim JH; Choi JH; Kim CH; Jung YK; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
    Scand J Gastroenterol; 2009; 44(3):346-57. PubMed ID: 18991165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DR-70 immunoassay for the surveillance of hepatocellular carcinoma.
    Lin SZ; Chen CC; Lee KC; Tseng CW; Lin HY; Chen YC; Lin HC
    J Gastroenterol Hepatol; 2012 Mar; 27(3):547-52. PubMed ID: 21883455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma.
    Diouf M; Filleron T; Barbare JC; Fin L; Picard C; Bouché O; Dahan L; Paoletti X; Bonnetain F
    J Hepatol; 2013 Mar; 58(3):509-21. PubMed ID: 23178978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential prognostic impact of renal insufficiency on patients with hepatocellular carcinoma: a propensity score analysis and staging strategy.
    Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Chiou YY; Lee RC; Lee FY; Huo TI; Lee SD
    J Gastroenterol Hepatol; 2012 Apr; 27(4):690-9. PubMed ID: 22436058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prognostic model for patients with hepatocellular carcinoma within the Milan criteria undergoing non-transplant therapies, based on 1106 patients.
    Lee YH; Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Chiou YY; Huo TI
    Aliment Pharmacol Ther; 2012 Sep; 36(6):551-9. PubMed ID: 22817677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.
    Hu HT; Kim JH; Lee LS; Kim KA; Ko GY; Yoon HK; Sung KB; Gwon DI; Shin JH; Song HY
    J Vasc Interv Radiol; 2011 Jul; 22(7):917-23. PubMed ID: 21571545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum C-reactive protein levels predict survival in hepatocellular carcinoma.
    Nagaoka S; Yoshida T; Akiyoshi J; Akiba J; Torimura T; Adachi H; Kurogi J; Tajiri N; Inoue K; Niizeki T; Koga H; Imaizumi T; Kojiro M; Sata M
    Liver Int; 2007 Oct; 27(8):1091-7. PubMed ID: 17845537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simple clinical prognostic model for hepatocellular carcinoma in developing countries and its validation.
    Tan CK; Law NM; Ng HS; Machin D
    J Clin Oncol; 2003 Jun; 21(12):2294-8. PubMed ID: 12805329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selecting a short-term prognostic model for hepatocellular carcinoma: comparison between the model for end-stage liver disease (MELD), MELD-sodium, and five cancer staging systems.
    Huo TI; Hsia CY; Huang YH; Lin HC; Lee PC; Lui WY; Chiang JH; Chiou YY; Loong CC; Lee SD
    J Clin Gastroenterol; 2009 Sep; 43(8):773-81. PubMed ID: 19262404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of clinical staging systems in predicting survival of hepatocellular carcinoma patients receiving major or minor hepatectomy.
    Chen TW; Chu CM; Yu JC; Chen CJ; Chan DC; Liu YC; Hsieh CB
    Eur J Surg Oncol; 2007 May; 33(4):480-7. PubMed ID: 17129701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.